Research and Markets: Generics Company Cipla Claims to Have Been the First Local Manufacturer to Introduce a Number of Products to the Indian Market, Including the Antiretrovirals Zidovudine, Stavudine, Lamivudine and Nevirapine.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c45980) has announced the addition of Cipla Generics Company Intelligence Report to their offering

Cipla was founded in Bombay in 1935, and released its first products in 1937. The company first gained US FDA approval for its bulk drug facilities in 1985. The company has seven facilities in India and is planning an eighth.

Sales for fiscal 2006 amounted to Rs 28,974.1 million (US$656 million). Revenue growth was driven by strong performances in both the Indian market and the international market. Sales were split evenly between Indian and non-Indian in 2006. Net income rose by 48.3% in 2006 to Rs 6,076. million.

Cipla manufactures APIs and formulation drugs, and its products are sold in over 150 countries. A number of the company's dosage forms and APIs are approved by regulatory agencies including the US FDA, the UK MHRA, Germany's PIC, South Africa's MCC, Australia's TGA, Health Canada and the WHO.

Cipla claims to have been the first local manufacturer to introduce a number of products to the Indian market, including the antiretrovirals zidovudine, stavudine, lamivudine and nevirapine. Other firsts have included propranolol, ondansetron, salmeterol, montelukast, fluticasone propionate and doxazosin. In 2006, the company announced it was launching an oseltamivir product in India. Oseltamivir is the generic form of Roche's Tamiflu.

Cipla gained global recognition in 2001 when it offered to export anti-AIDS drug for less than US$1 a day. The WHO added the company's antiretrovirals to its prequalification list. However, in mid-2004, it removed two of Cipla's drugs, after questions were raised about the contract research organisation Cipla used to carry out bioequivalence studies. The drugs were placed back on the list in December 2004, after successfully completing new bioequivalence studies.

These generics company reports from Espicom will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.

The easy and cost effective way to monitor developments in leading generic drug industry players.

Generics Company Reports from Espicom are packed with facts, figures and statistics, providing you with the most thorough ongoing monitoring of the important generic companies. From financial performance to litigation, no other service provides such comprehensive insight to the companies driving growth in this rapidly expanding area of the pharmaceutical industry.

Each report is updated and issued every quarter. This ongoing monitoring and regular delivery ensures that developments are incorporated into the relevant reports. This vigilance ensures that whether it's the latest deals, ANDAs, alliances or litigation you can assess the impact of the development in the context of the company, its competitors and the broader market.

Use Generic Company Reports to:

- Evaluate the competitive operating environment.

- Identify which companies are applying for ANDAs, and for what.

- Understand generic companies' product line up.

- Monitor the financial performance of leading generics players.

- Track the twists and turns of litigation.

Stay in touch with the latest M&A and strategic alliances

Topics Covered:

- Introduction

- Products

- Financial results

- Major developments

- HIV/AIDS 

Companies Mentioned:

- Akorn

- Enaleni

- Pentech Pharmaceuticals

- Avestha Gengraine Technologies

- Morton Grove Pharmaceuticals

- Watson Pharmaceuticals

- Stada

- Hexal

- Fujisawa

For more information visit http://www.researchandmarkets.com/reports/c45980

Source: Espicom Business Intelligence Ltd.